Regeneron Pharmaceuticals, Inc.
Close on Nov 20, 2026Market cap $95.24BP/E 20.3Yield –
Regeneron Pharmaceuticals Indirect R&D by Quarter
Indirect R&D — Occupancy and Other Operating Costs ($M) ($M)
Regeneron Pharmaceuticals Indirect R&D: $176M in Q3 2026, up 5.7% from a year earlier.
Where the Q3 2026 figure comes from
“R&D Expenses Table (FY2026Q3): Occupancy and other operating costs | 175.7 | 166.3 | 9.4 | 528.6 | 479.2 | 49.4”
Source: Form 10-Q (regn-20260930.htm, filed 2026-10-30) ↗
Reported in Form 10-Q / 10-K MD&A — Research and Development Expenses Summary Table.
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Regeneron Pharmaceuticals Indirect R&D ($M), quarterly Q1 2017–Q3 2026 [Data set]. Compiled from Regeneron Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/regn/kpis/rd-indirect-occ
See every metric in the Regeneron Pharmaceuticals KPI table. Data updated Nov 4, 2026.
See a number that looks wrong?